Drugs & Medications

Guanfacine Reverses Cognitive Impairment in Long COVID (2024 Case Report)

by

Guanfacine extended release (GXR) may effectively improve cognitive impairments and brain activity in long-COVID patients. Highlights: Patient Presentation: A 32-year-old woman experienced cognitive impairments such as difficulty in word recall, reading, and writing, and delayed task completion following COVID-19 infection. Baseline Assessment: Initial tests showed poor performance in attention, working memory, and executive function, with …

Read more

Antidepressant Efficacy vs. CYP2C19 & CYP2D6 Metabolism Genetics (2024 Review)

by

CYP2C19 poor metabolizers showed a nominally higher antidepressant remission rate compared to normal metabolizers, but overall genetic variations in CYP2C19 and CYP2D6 were not significantly associated with antidepressant response. Highlights: Higher Remission Rate: CYP2C19 poor metabolizers had a nominally higher remission rate (OR = 1.46) compared to normal metabolizers, but this did not hold after …

Read more

LIT-001 (Oxytocin Receptor Agonist) Alters Pair Bonding in Prairie Voles (2024 Study)

by

A small-molecule oxytocin receptor-specific agonist, LIT-001, differentially affects the acquisition and expression of partner preference in prairie voles, enhancing bonding when administered before cohabitation but inhibiting it when given afterward. Highlights: LIT-001 Enhances Bonding Pre-Cohabitation: Administration of LIT-001 (10 mg/kg) before a 4-hour cohabitation period facilitated the acquisition of partner preference in male prairie voles. …

Read more

Necrostatin-1: A Necroptosis Inhibitor to Treat Neurological Disorders (2024 Research)

by

Necrostatin-1, an inhibitor of necroptosis, exhibits significant neuroprotective effects and potential therapeutic applications in various neurological disorders by modulating cell death pathways, inflammation, and reactive oxygen species. Highlights: Mechanism of Action: Necrostatin-1 specifically inhibits receptor-interacting protein 1 (RIP1), preventing necroptosis and other cell death pathways, including apoptosis and ferroptosis. Neuroprotective Role: It shows promise in …

Read more

Nanoparticle Enhanced Radiotherapy (NERT) for Brain Tumor Treatment (2024 Research)

by

Nanoparticle-enhanced radiotherapy (NERT) is a promising approach to improving brain tumor treatment by enhancing radiotherapy efficacy through targeted delivery and radiosensitization while overcoming challenges posed by the blood-brain barrier. Highlights: Mechanisms of Action: NERT utilizes nanoparticles (NPs) as radiosensitizers, enhancing radiation-induced damage through physical dose enhancement and biological/chemical sensitization. Types of Nanoparticles: Various NP types, …

Read more

Cocaine Addiction Linked to Brain Shrinkage & Grey Matter Deficits (2024 Study)

by

Cocaine Use Disorder (CUD) patients exhibit widespread gray matter atrophy, with specific brain volume deficits associated with crack-cocaine use and relapse outcomes. Highlights: Widespread Gray Matter Atrophy: CUD patients show significant gray matter volume reductions in frontal and temporal cortices, cerebellum, and subcortical structures compared to healthy controls. Route of Use: Crack-cocaine use is linked …

Read more

OCD Treatment with Antidepressants (SSRIs) Alters Brain Structure & Functions (2024 Study)

by

Antidepressant treatment in OCD is linked to structural and functional brain changes, particularly in corticosubcortical areas, but these findings need further validation in larger, more homogeneous samples. Highlights: Antidepressant Use: Antidepressants, especially SSRIs, are a primary treatment for OCD, resulting in significant brain changes. Brain Structure Changes: Studies show volume alterations in the thalamus, amygdala, …

Read more

Lithium Appears Neuroprotective in Traumatic Brain Injury (TBI) (2024 Research)

by

Lithium shows promise in treating traumatic brain injury (TBI) by mitigating neuroinflammation, protecting against neuronal damage, and improving cognitive functions. Highlights: Neuroprotective Mechanisms: Lithium’s therapeutic effects involve complex molecular mechanisms including gene expression, neurotransmitter signaling, and circadian modulation, contributing to neuronal protection and recovery post-TBI. Targeted Brain Regions: Post-treatment, lithium concentrations are notably higher in …

Read more

Selegiline Reverses Anxiety & Memory Impairment in Amyloid Beta-Induced Alzheimers Model Rats (2024 Study)

by

The study demonstrated that selegiline (SEL) improves memory performance, reduces anxiety, and modulates oxidative stress in an Alzheimer’s disease (AD) rat model. Highlights: Memory Improvements: SEL administration improved recognition memory, spatial memory, and passive avoidance memory in AD rats. Anxiety Reduction: SEL significantly reduced anxiety-like behavior in AD rats, as evidenced by performance in the …

Read more

Repurposing Antipsychotics & Antidepressants to Treat Glioblastoma (2024 Study)

by

Repurposing antipsychotics and antidepressants with favorable safety profiles and blood-brain barrier permeability shows promise for glioblastoma (GBM) treatment, primarily through disrupting lysosomal function and inducing cell death. Highlights: Mechanism of Action: The studied antipsychotics and antidepressants induce GBM cell death by disrupting lysosomal function, leading to lysosomal membrane rupture. PTEN Sensitivity: GBMs with intact PTEN …

Read more

+ Load more